Cargando…

Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans

Renal toxicity is more common with tenofovir disoproxil fumarate (TDF) than with tenofovir alafenamide fumarate (TAF). We investigated whether polymorphisms in genes relevant to tenofovir disposition affect renal toxicity among HIV-positive Southern Africans. METHODS: Genetic sub-study of adults ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mateza, Somila, Bradford, Yuki, Maartens, Gary, Sokhela, Simiso, Chandiwana, Nomathemba C., Venter, Willem D.F., Post, Frank A., Ritchie, Marylyn D., Haas, David W., Sinxadi, Phumla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234323/ https://www.ncbi.nlm.nih.gov/pubmed/37099271 http://dx.doi.org/10.1097/FPC.0000000000000491

Ejemplares similares

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV
por: Mondleki, Enkosi, et al.
Publicado: (2022)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
por: Decloedt, Eric H., et al.
Publicado: (2021)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Weight gain on dolutegravir: Association is not the same as causation
por: Maartens, Gary, et al.
Publicado: (2023)

Leveraging Multi-Ancestry Polygenic Risk Scores for Body Mass Index to Predict Antiretroviral Therapy-Induced Weight Gain*
por: Keat, Karl, et al.
Publicado: (2023)

An overview of tenofovir and renal disease for the HIV-treating clinician
por: Venter, Willem D.F., et al.
Publicado: (2018)

Integration of point-of-care screening for type 2 diabetes mellitus and hypertension into the COVID-19 vaccine programme in Johannesburg, South Africa
por: Brennan, Alana T, et al.
Publicado: (2023)

Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial
por: Venter, Willem Daniel Francois, et al.
Publicado: (2019)

Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations
por: Sinxadi, Phumla Zuleika, et al.
Publicado: (2016)

Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study
por: Sinxadi, Phumla Z, et al.
Publicado: (2012)

Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic
por: Pepperrell, Toby, et al.
Publicado: (2020)

Validation of a quantitative multiplex LC-MS/MS assay of carvedilol, enalaprilat, and perindoprilat in dried blood spots from heart failure patients and its cross validation with a plasma assay
por: Joubert, Andre, et al.
Publicado: (2022)

Southern African HIV Clinicians Society guidelines for harm reduction
por: Scheibe, Andrew, et al.
Publicado: (2020)

The cost of adding rapid screening for diabetes, hypertension, and COVID-19 to COVID-19 vaccination queues in Johannesburg, South Africa
por: Masuku, Sithabiso D., et al.
Publicado: (2023)

Towards Evidence-Based Implementation of Pharmacogenomics in Southern Africa: Comorbidities and Polypharmacy Profiles across Diseases
por: Soko, Nyarai Desiree, et al.
Publicado: (2023)

Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study
por: Sinxadi, Phumla Z, et al.
Publicado: (2010)

Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
por: Sokhela, Simiso, et al.
Publicado: (2022)

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population
por: Verma, Shefali S., et al.
Publicado: (2022)

Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression()
por: Li, Binglan, et al.
Publicado: (2018)

Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa
por: Chandiwana, Nomathemba C., et al.
Publicado: (2021)

High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa
por: Chandiwana, Nomathemba, et al.
Publicado: (2018)

Community-based management of a five-arm randomised clinical trial in COVID-19 outpatients in South Africa: challenges and opportunities
por: Chandiwana, Nomathemba, et al.
Publicado: (2023)

Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors
por: Pepper, Dominique J, et al.
Publicado: (2010)

Influence of tissue context on gene prioritization for predicted transcriptome-wide association studies
por: Li, Binglan, et al.
Publicado: (2019)

The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen
por: Venter, Willem D.F., et al.
Publicado: (2017)

Southern African HIV Clinicians Society 2023 Guideline for post-exposure prophylaxis: Updated recommendations
por: Horak, Jaco, et al.
Publicado: (2023)

Southern African HIV Clinicians Society 2022 guideline for the management of sexually transmitted infections: Moving towards best practice
por: Peters, Remco P.H., et al.
Publicado: (2022)

Erratum: Southern African HIV Clinicians Society 2022 guideline for the management of sexually transmitted infections: Moving towards best practice
por: Peters, Remco P.H., et al.
Publicado: (2022)

Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202
por: Verma, Anurag, et al.
Publicado: (2017)

Pharmacogenetics of Anticoagulants
por: Rane, Anders, et al.
Publicado: (2010)

Understanding adherence in virally suppressed and unsuppressed human immunodeficiency virus-positive urban patients on second-line antiretroviral treatment
por: Gumede, Siphamandla B., et al.
Publicado: (2020)

Warfarin Anticoagulant Therapy: A Southern Italy Pharmacogenetics-Based Dosing Model
por: Mazzaccara, Cristina, et al.
Publicado: (2013)

Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update
por: Nel, Jeremy, et al.
Publicado: (2020)

A simulation study investigating power estimates in phenome-wide association studies
por: Verma, Anurag, et al.
Publicado: (2018)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial
por: Chandiwana, Nomathemba, et al.
Publicado: (2022)

Profile of presentation of HIV-positive patients to an emergency department in Johannesburg, South Africa
por: Laher, Abdullah E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fg89ut6cope9noesepe9h30839